[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612282":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":42,"centralContacts":42,"locations":42,"responsibleParty":43,"collaborators":42,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":42,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":42,"enrollmentInfo":56,"targetDuration":42,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":42,"overallStatus":65,"whyStopped":42,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":42},{"fullName":5,"class":6},"Chinese University of Hong Kong","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"semaglutide","EXPERIMENTAL","Patients in the treatment group will be started on an initial dose of semaglutide 0.25 mg once weekly for 4 weeks to assess the tolerability of the drug and to minimize potential gastrointestinal side effects. Then 4 weeks the dose will be increased to 0.5 mg once weekly. After 8 weeks the dose will be increased to 1.0mg once weekly for a total treatment period of 24 weeks.",[13,14,15],"Drug: Semaglutide 0.5 mg","Drug: Semaglutide 1.0 mg","Drug: Semaglutide 0.25 mg",{"label":17,"type":6,"description":18,"interventionNames":19},"Control","No active drug administered",[20],"Other: No intervention",[22,29,34,39],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Semaglutide 0.5 mg","Then 4 weeks the dose will be increased to 0.5 mg once weekly.",[9],[28],"ozempic",{"type":23,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Semaglutide 1.0 mg","1.0 mg once weekly for 16 weeks",[9],[28],{"type":23,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"Semaglutide 0.25 mg","Initial dose of semaglutide 0.25 mg once weekly for 4 weeks to assess the tolerability of the drug and to minimize potential gastrointestinal side effects.",[9],[28],{"type":6,"name":40,"description":40,"armGroupLabels":41,"otherNames":42},"No intervention",[17],null,{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"PRINCIPAL_INVESTIGATOR","Ho SO","Assistant Professor","100612282","phase-4-glp-1-receptor-agonists-in-non-diabetic-patients-with-psoriatic-arthritis-100612282",false,"NCT07251556","GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis","Effect of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Subclinical Atherosclerosis in Non-diabetic Patients With Psoriatic Arthritis - a Proof-of-concept Randomized Study","Inclusion Criteria:\n\n1. fulfill the ClASsification criteria for Psoriatic Arthritis,\n2. are rheumatoid factor negative,\n3. BMI \\>=25 kg\u002Fm2,\n4. are over 18 years old and\n5. Chinese subjects\n\nExclusion Criteria:\n\n1. have prior therapy with GLP-1 receptor agonists during the last 24 weeks,\n2. have pre-existing diabetes,\n3. have liver or renal impairment,\n4. have known or symptoms suggestive of CVD,\n5. have chronic or previous acute pancreatitis,\n6. have current malignancy,\n7. are pregnant, breastfeeding or of childbearing potential, or\n8. are unable to give written informed consent.","ALL","18 Years",{"count":57,"type":58},40,"ESTIMATED","INTERVENTIONAL",[61],"PHASE4","Background Psoriatic arthritis (PsA) patients are at increased risk of cardiovascular disease. Glucagon-Like Peptide-1 (GLP-1) receptor agonists are cardiovascular protective in diabetics. They have also anti-inflammatory properties. It is hypothesized GLP-1 receptor agonists can prevent the progression of atherosclerosis due to the combination of metabolic factors and disease activity control in non-diabetic PsA patients.\n\nObjectives To investigate the vascular effects of GLP-1 receptor agonists in PsA patients without diabetes. Their metabolic and anti-inflammatory roles will also be examined.\n\nDesign and subjects This is a pilot randomized open-labelled trial. We plan to enroll 40 non-diabetic patients with PsA. Participants will be randomized 1:1 to either GLP-1 receptor agonist (semaglutide) or control group.\n\nStudy instruments Subclinical carotid artherosclerosis is assessed by high-resolution ultrasound. Arterial stiffness is measured using pulse wave velocity by a tonometry system, and augmentation index by the SphygmoCor device. These assessments will be done at baseline and 24 weeks. Drug adversities will also be documented. Anthropometric measurements, sugar metabolism and lipid levels as well as the PsA disease activity will be monitored.",[64],"Psoriasis Arthritis","NOT_YET_RECRUITING","2025-11-25",{"date":68,"type":69},"2025-12-02","ACTUAL",{"date":71,"type":58},"2025-12-01",{"date":73,"type":58},"2027-01-01",{"name":5,"class":6}]